Pacer Data and Digital Revolution ETF (TRFK)
- Previous Close
40.14 - Open
40.81 - Bid 37.04 x 900
- Ask 42.00 x 1100
- Day's Range
40.73 - 40.97 - 52 Week Range
24.79 - 45.28 - Volume
6,518 - Avg. Volume
19,246 - Net Assets 31.07M
- NAV 40.85
- PE Ratio (TTM) 38.80
- Yield 0.14%
- YTD Daily Total Return 11.36%
- Beta (5Y Monthly) 0.00
- Expense Ratio (net) 0.60%
The fund employs a “passive management” (or indexing) investment approach designed to track the total return performance, before fees and expenses, of the index. The index is a rules-based index that consists of globally-listed stocks and depositary receipts of companies. The fund is non-diversified.
Pacer
Fund Family
Technology
Fund Category
31.07M
Net Assets
2022-06-08
Inception Date
Performance Overview: TRFK
Trailing returns as of 4/26/2024. Category is Technology.
People Also Watch
Holdings: TRFK
Top 10 Holdings (60.73% of Total Assets)
Sector Weightings
Recent News: TRFK
Research Reports: TRFK
CTRA: Raising target price to $25.00
COTERRA ENERGY INC has an Investment Rating of SELL; a target price of $25.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCTRA: Lowering target price to $24.00
COTERRA ENERGY INC has an Investment Rating of SELL; a target price of $24.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetCTRA: What does Argus have to say about CTRA?
COTERRA ENERGY INC has an Investment Rating of SELL; a target price of $25.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetAnalyst Report: Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice Target